Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, PR China; Department of Pediatric Urology Surgery, Children's Hospital of Chongqing Medical University, Chongqing 400014, PR China.
Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, PR China.
Biomed Pharmacother. 2020 May;125:109880. doi: 10.1016/j.biopha.2020.109880. Epub 2020 Jan 28.
MicroRNA-155-5p (miR-155-5p) has been reported to play an oncogenic role in different human malignancies; however, its role in Wilms tumor (WT) remains unclear.
Differentially expressed miRNAs (DE-miRNAs) and mRNAs (DEGs) in WT blood and tissues were identified by using miRNA microarray and RNA-sequencing. Bioinformatics prediction and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to predict the potential functions of DE-miRNAs. DE-miRNAs and DEGs in WT obtained from Gene Expression Omnibus (GEO) and Therapeutically Applicable Research to Generate Effective Treatments (TARGET) were identified by using the "edgeR" package. RT-qPCR was used to explore miR-155-5p and IGF2 expression and their clinical significance in WT specimens. A rhabdoid cell line (G401) and Ewing sarcoma cell line (SK-NEP-1) were used. Immunohistochemical staining, western blotting and dual-luciferase reporter assays were performed to study the mechanisms involved. The CCK-8, flow cytometry, wound healing and transwell assays were performed to identify the effects of miR-155-5p and IGF2 knockdown on cell proliferation, apoptosis, migration and invasion, respectively.
MiR-155-5p was downregulated in both blood and tissues from WT patients who did not receive chemotherapy before surgery but was upregulated in tissues from WT patients who had received chemotherapy before surgery. IGF2, PI3K, AKT and mTOR were found to be upregulated in WT tissues. Additionally, miR-155-5p and IGF2 were significantly correlated with TNM stage and lymphatic metastasis in WT patients. Molecular mechanism exploration indicated that IGF2 was downregulated by miR-155-5p via direct binding to its 3' untranslated region in cell lines. Furthermore, IGF2, PI3K, AKT and mTOR expression was inversely correlated with miR-155-5p expression, and PI3K, AKT and mTOR expression was positively correlated with IGF2 expression in cell culture. Functional studies demonstrated that miR-155-5p upregulation and IGF2 knockdown suppressed cell proliferation, migration and invasion and induced cell apoptosis. Moreover, the tumor-suppressing effects of miR-155-5p in cells were abrogated by miR-155-5p inhibitor treatment.
Taken together, these findings suggest that miR-155-5p functions as a tumor suppressor in WT through inactivating the PI3K/AKT/mTOR signaling pathway by directly targeting IGF2. Thus, miR-155-5p might be a novel therapeutic target for WT.
MicroRNA-155-5p(miR-155-5p)已被报道在不同的人类恶性肿瘤中发挥致癌作用;然而,其在肾母细胞瘤(WT)中的作用尚不清楚。
通过 miRNA 微阵列和 RNA-seq 鉴定 WT 血液和组织中的差异表达 miRNA(DE-miRNA)和 mRNA(DEG)。使用京都基因与基因组百科全书(KEGG)富集分析预测 DE-miRNA 的潜在功能。通过“edgeR”包鉴定从基因表达综合数据库(GEO)和治疗应用研究生成有效治疗方法(TARGET)获得的 WT 中的 DE-miRNA 和 DEG。使用 RT-qPCR 探索 WT 标本中 miR-155-5p 和 IGF2 的表达及其临床意义。使用横纹肌肉瘤细胞系(G401)和尤文肉瘤细胞系(SK-NEP-1)进行实验。进行免疫组织化学染色、Western blot 和双荧光素酶报告基因实验,以研究涉及的机制。进行 CCK-8、流式细胞术、划痕愈合和 Transwell 实验,以分别鉴定 miR-155-5p 和 IGF2 敲低对细胞增殖、凋亡、迁移和侵袭的影响。
miR-155-5p 在未接受化疗的 WT 患者的血液和组织中下调,但在接受化疗的 WT 患者的组织中上调。IGF2、PI3K、AKT 和 mTOR 在 WT 组织中上调。此外,miR-155-5p 和 IGF2 与 WT 患者的 TNM 分期和淋巴转移显著相关。分子机制研究表明,IGF2 通过直接与其 3'UTR 结合在细胞系中被 miR-155-5p 下调。此外,在细胞培养中,IGF2、PI3K、AKT 和 mTOR 的表达与 miR-155-5p 的表达呈负相关,IGF2 的表达与 PI3K、AKT 和 mTOR 的表达呈正相关。功能研究表明,miR-155-5p 的上调和 IGF2 的敲低抑制细胞增殖、迁移和侵袭,并诱导细胞凋亡。此外,miR-155-5p 抑制剂处理可消除 miR-155-5p 在细胞中的抑瘤作用。
综上所述,这些发现表明,miR-155-5p 通过直接靶向 IGF2 使 PI3K/AKT/mTOR 信号通路失活,从而在 WT 中发挥肿瘤抑制作用。因此,miR-155-5p 可能成为 WT 的一种新的治疗靶点。